GO:0005248 voltage-gated sodium channel activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005248 voltage-gated sodium channel activity describes the molecular function that enables voltage-dependent transmembrane transfer of sodium ions.
• Voltage-gated sodium channels (Nav channels) are large multi-domain membrane proteins whose opening is controlled by changes in membrane potential.
• Nine mammalian Nav channel alpha subunits (Nav1.1-Nav1.9, encoded by SCN1A-SCN11A) plus auxiliary beta subunits form the core molecular machinery.
• Nav channels are central to action potential initiation and propagation in excitable cells and are validated drug targets for pain, epilepsy, and arrhythmia.
• Dysregulated Nav channel expression or gating is implicated in cancer, chronic pain, and neurological disorders, making them attractive experimental models.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal dissection of Nav channel function and pharmacology.
Description
Voltage-gated sodium channel activity (GO:0005248) is the molecular function by which a membrane protein permits sodium ions to cross the lipid bilayer in a manner that depends on the voltage across the membrane. This activity underlies the rapid upstroke of the action potential in neurons, cardiac myocytes, and skeletal muscle, and it is therefore one of the most intensively studied ion-channel functions in physiology and pharmacology. The channels responsible are large, pseudo-tetrameric proteins composed of four homologous domains, each containing six transmembrane helices, with a voltage-sensing module and a selective pore. Because the open state is voltage-dependent, the activity is tightly coupled to membrane excitability and to cellular signaling cascades that modulate channel trafficking and gating. Researchers study GO:0005248 to understand excitability disorders, to discover analgesics and antiarrhythmics, and to define how Nav channel isoforms contribute to cancer and other diseases. The availability of structural, electrophysiological, and CRISPR-based tools has made this term a focal point for both basic and translational investigation.
voltage-gated sodium channel activity At A Glance
| GO ID | GO:0005248 |
|---|---|
| GO term | voltage-gated sodium channel activity |
| Ontology | molecular_function |
| Synonym | voltage-dependent sodium channel activity; voltage gated sodium channel activity; voltage-gated sodium ion channel activity; voltage-sensitive sodium channel |
| Major function | Voltage-dependent transmembrane transfer of sodium ions |
| Molecular context | Pore-forming alpha subunits (Nav1.1-Nav1.9) with auxiliary beta subunits |
| Voltage dependence | Open state is controlled by the membrane potential across the bilayer |
| Ion selectivity | Sodium-selective permeation pathway |
| Representative genes | SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, SCN11A |
What Is GO:0005248?
In simple terms, GO:0005248 describes the job of a protein that opens a sodium-selective pore in response to voltage changes across the membrane. The official QuickGO definition states that this activity enables the transmembrane transfer of a sodium ion by a voltage-gated channel, where a voltage-gated channel is one whose open state depends on the voltage across the membrane in which it is embedded. The term is a molecular_function in the Gene Ontology and includes synonyms such as voltage-dependent sodium channel activity, voltage gated sodium channel activity, voltage-gated sodium ion channel activity, and voltage-sensitive sodium channel.
Why Is voltage-gated sodium channel activity Important in Cell Biology?
Voltage-gated sodium channel activity is essential for electrical signaling in excitable tissues and is a major determinant of neuronal firing, cardiac rhythm, and muscle contraction. Because Nav channels are the primary mediators of the fast depolarizing phase of action potentials, even small changes in their gating, trafficking, or expression can produce profound physiological effects. This makes GO:0005248 a high-value target for understanding disease mechanisms and for developing therapeutics, including analgesics, anticonvulsants, and antiarrhythmics. In addition, Nav channel isoforms are increasingly recognized as contributors to non-excitable disease processes such as cancer cell invasion and proliferation. Consequently, researchers across neuroscience, cardiology, oncology, and pharmacology rely on this GO term to annotate and interpret gene function.
• Underlies action potential initiation and propagation in neurons, cardiac myocytes, and skeletal muscle.
• Provides the molecular basis for fast electrical signaling and excitability.
• Is a validated target for local anesthetics, anticonvulsants, and antiarrhythmic drugs.
• Contributes to chronic pain syndromes through Nav1.7, Nav1.8, and Nav1.9 isoforms.
• Is implicated in epilepsy and neurodevelopmental disorders via SCN1A, SCN2A, and SCN8A mutations.
• Plays a role in cancer biology, including glioma proliferation and invasion.
• Is modulated by trafficking and protein-protein interactions that regulate channel density at the membrane.
• Serves as a model system for studying voltage sensing and slow inactivation mechanisms.
• Is targeted by natural toxins such as scorpion alpha-toxins and mu-conotoxins, which are research tools and drug leads.
• Enables structure-function studies using AlphaFold2 and cryo-EM to guide drug design.
Molecular Mechanism of voltage-gated sodium channel activity
Voltage sensing and activation
In simple terms: The channel senses changes in voltage and opens in response.
Voltage-gated sodium channels contain four voltage-sensing domains, each formed by a positively charged S4 helix. Depolarization of the membrane moves these S4 segments outward, which triggers a conformational change that opens the pore. This electromechanical coupling is the defining feature of GO:0005248 and allows the channel to respond rapidly to changes in membrane potential.
Ion permeation and selectivity
In simple terms: Once open, the channel lets sodium ions flow through while blocking other ions.
The pore of Nav channels is lined by the P-loop of each domain, which forms the selectivity filter. This filter permits sodium ions to pass while excluding larger ions, enabling the rapid influx of sodium that depolarizes the cell. The structural basis of ion selectivity has been resolved in several channel structures and is a key aspect of the molecular function.
Fast inactivation
In simple terms: The channel closes quickly after opening to prevent continuous sodium flow.
Fast inactivation is mediated by the intracellular loop between domains III and IV, which acts as a hinged lid that occludes the pore. This process terminates the sodium current within milliseconds and is essential for action potential repolarization. Mutations that impair fast inactivation can cause hyperexcitability disorders.
Slow inactivation
In simple terms: The channel can also enter a long-lasting closed state during sustained depolarization.
Slow inactivation occurs over seconds to minutes and involves conformational changes in the pore and voltage-sensing domains. Recent structural studies have revealed how the selectivity filter and S6 segments rearrange during slow inactivation. This process modulates channel availability and is important for firing frequency adaptation.
Auxiliary subunits and modulation
In simple terms: Accessory proteins attach to the channel and tune its behavior.
Beta subunits (encoded by SCN1B-SCN4B) associate with the alpha subunit and modulate gating, trafficking, and cell adhesion. They also interact with cell adhesion molecules and extracellular matrix proteins, influencing channel localization. These interactions expand the regulatory repertoire of GO:0005248 and are targets for pharmacological intervention.
Pharmacology and toxin binding
In simple terms: Drugs and toxins can block or modify the channel to alter its activity.
Nav channels are inhibited by local anesthetics, anticonvulsants, and antiarrhythmics that bind within the pore. Natural toxins such as mu-conotoxins and scorpion alpha-toxins modulate channel gating with high specificity. These compounds are invaluable for probing channel structure and for developing new therapeutics.
Key Genes Involved in GO:0005248 voltage-gated sodium channel activity
The following genes encode the principal alpha and beta subunits that mediate or modulate voltage-gated sodium channel activity in humans.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCN1A | Nav1.1 alpha subunit; brain | Epilepsy, Dravet syndrome; fast inactivation studies |
| SCN2A | Nav1.2 alpha subunit; brain | Neurodevelopmental disorders; channelopathy models |
| SCN3A | Nav1.3 alpha subunit; brain | Embryonic expression; pain and epilepsy research |
| SCN4A | Nav1.4 alpha subunit; skeletal muscle | Myotonia, periodic paralysis; gating studies |
| SCN5A | Nav1.5 alpha subunit; heart | Cardiac arrhythmia, Brugada syndrome; drug screening |
| SCN8A | Nav1.6 alpha subunit; brain | Epileptic encephalopathy; resurgent current |
| SCN9A | Nav1.7 alpha subunit; PNS | Chronic pain, erythromelalgia; analgesic target |
| SCN10A | Nav1.8 alpha subunit; PNS | Pain signaling; tetrodotoxin-resistant current |
| SCN11A | Nav1.9 alpha subunit; PNS | Pain and inflammation; channelopathy models |
| SCN1B | Beta1 subunit | Modulates gating and trafficking; epilepsy |
| SCN2B | Beta2 subunit | Cell adhesion and channel localization |
| SCN3B | Beta3 subunit | Cardiac and neuronal excitability |
| SCN4B | Beta4 subunit | Channel modulation in brain and heart |
| SCN7A | Nav2.1 (atypical) | Non-voltage-gated sodium channel; cancer |
| SCN1A-AS1 | Antisense RNA | Regulation of SCN1A expression |
| FGF13 | Fibroblast growth factor 13 | Modulates Nav1.7 trafficking and pain |
| CALM1 | Calmodulin | Calcium-dependent regulation of Nav channels |
| ANK3 | Ankyrin-G | Anchors Nav channels at nodes of Ranvier |
How Is voltage-gated sodium channel activity Regulated?
Voltage-gated sodium channel activity is regulated at multiple levels. At the channel level, gating is controlled by membrane voltage and by intracellular factors such as calmodulin, which binds to IQ motifs in the C-terminus and modulates inactivation. Protein-protein interactions with ankyrin-G and other cytoskeletal proteins regulate channel clustering at specific membrane domains. Trafficking and surface expression are controlled by beta subunits and by post-translational modifications, including phosphorylation and ubiquitination. In addition, slow inactivation provides a use-dependent form of regulation that limits channel availability during sustained depolarization. These regulatory mechanisms are critical for matching channel activity to physiological demand and are often disrupted in disease.
voltage-gated sodium channel activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCN1A | Dravet syndrome, epilepsy | Knock-in of patient mutation in iPSC-derived neurons |
| SCN5A | Brugada syndrome, arrhythmia | Overexpression in HEK293 cells for patch-clamp |
| SCN9A | Erythromelalgia, pain | Point mutation knock-in in sensory neurons |
| SCN8A | Epileptic encephalopathy | Knockout in mouse models and cell lines |
| SCN7A | Glioma progression | Knockdown/knockout in glioma cell lines |
Epilepsy and neurodevelopmental disorders
Mutations in SCN1A, SCN2A, and SCN8A are associated with epilepsy and neurodevelopmental disorders such as Dravet syndrome and epileptic encephalopathy. These mutations often alter fast inactivation or voltage dependence, leading to neuronal hyperexcitability. Research models using patient-derived mutations in cell lines and animal models have clarified how specific gating defects produce disease phenotypes.
Chronic pain
Nav1.7, Nav1.8, and Nav1.9 are preferentially expressed in peripheral sensory neurons and are validated targets for pain management. Gain-of-function mutations in SCN9A cause erythromelalgia, while loss-of-function mutations cause congenital insensitivity to pain. Analgesic development efforts focus on subtype-selective inhibitors and on modulating channel trafficking.
Cardiac arrhythmias
SCN5A mutations are linked to Brugada syndrome, long QT syndrome type 3, and cardiac conduction defects. These channelopathies alter sodium current amplitude or kinetics, affecting cardiac action potential duration and propagation. Experimental models using heterologous expression and cardiomyocytes have been essential for characterizing these defects.
Cancer
Voltage-gated sodium channels, particularly Nav1.6 and the atypical SCN7A, are expressed in some cancers and contribute to proliferation, migration, and invasion. In glioma, Nav1.6 activity has been implicated in cell migration and is being explored as a therapeutic target. Screening of candidate drugs against Nav channels in cancer models is an active area of research.
From voltage-gated sodium channel activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SCN1A affect neuronal excitability? | CRISPR knockout in iPSC-derived neurons |
| How does a specific SCN5A mutation alter gating? | Point mutation knock-in in HEK293 or CHO cells |
| Can a fluorescent tag track Nav1.7 trafficking? | Knock-in of tagged SCN9A in sensory neurons |
| Does overexpression of SCN7A promote glioma migration? | Overexpression in glioma cell lines |
| Which beta subunit modulates Nav1.5 inactivation? | Co-expression of SCN5A with SCN1B-SCN4B in heterologous cells |
| Can CRISPR library screening identify modifiers of Nav channel function? | Genome-wide knockout library in excitable cell lines |
How to Study the voltage-gated sodium channel activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Ionic currents and gating kinetics | Characterizing mutant Nav channels |
| Cryo-EM | Three-dimensional channel structure | Understanding voltage sensing and inactivation |
| AlphaFold2 modeling | Predicted conformations and interactions | Guiding mutagenesis and drug design |
| Fluorescence microscopy | Channel localization and trafficking | Studying beta subunit effects |
| RNA-seq | Gene expression levels | Profiling SCN genes in disease models |
| CRISPR library screening | Gene function at scale | Identifying modifiers of Nav activity |
| Toxin binding assays | Channel-toxin interactions | Developing subtype-selective probes |
| Automated patch-clamp | Compound effects on channel activity | High-throughput drug screening |
Electrophysiology
Patch-clamp recording is the gold-standard method to measure voltage-gated sodium channel activity directly. It provides detailed information on activation, inactivation, and recovery kinetics, and is used to characterize mutant channels and drug effects. Automated patch-clamp platforms enable higher-throughput screening of compounds.
Structural biology and computational modeling
Cryo-electron microscopy and X-ray crystallography have resolved Nav channel structures in multiple states. AlphaFold2 and molecular dynamics simulations complement these structures by predicting conformations and protein-protein interactions. These approaches guide mutagenesis and drug design.
Fluorescence imaging and trafficking assays
Tagged channels and subunit-specific antibodies allow visualization of channel localization and trafficking in live cells. Total internal reflection fluorescence (TIRF) and super-resolution microscopy reveal nanoscale clustering at the membrane. These methods link channel activity to cellular architecture.
Genomic and transcriptomic profiling
RNA-seq and single-cell transcriptomics quantify SCN gene expression across tissues and disease states. CRISPR screening combined with sequencing identifies genes that modify Nav channel function or expression. These approaches are powerful for discovering new regulatory pathways.
How CRISPR Can Be Used to Study GO:0005248 voltage-gated sodium channel activity
Knockout
CRISPR knockout of SCN genes in cell lines or iPSC-derived neurons eliminates specific Nav channel subunits, allowing researchers to determine their contribution to sodium currents and excitability. Knockout models are also used to validate drug targets and to study compensatory changes in other channels.
Point Mutation
Introducing disease-associated point mutations (e.g., in SCN1A or SCN5A) via CRISPR base editing or homology-directed repair creates isogenic models to study gating defects and drug responses. These models are essential for linking genotype to electrophysiological phenotype.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous SCN loci enables real-time tracking of channel trafficking and localization without overexpression artifacts. Tagged knock-in models are valuable for studying beta subunit interactions and membrane clustering.
Overexpression
CRISPR activation or cDNA overexpression of SCN genes in heterologous cells or cancer cell lines is used to study channel function in isolation or to model gain-of-function states. Overexpression models are particularly useful for drug screening and for studying non-excitable cell behaviors.
How EDITGENE Supports voltage-gated sodium channel activity Research
Researchers studying voltage-gated sodium channel activity-related genes often need to determine whether a candidate gene is causally involved in channel function, trafficking, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for voltage-gated sodium channel activity research.
Frequently Asked Questions About voltage-gated sodium channel activity
What is voltage-gated sodium channel activity?
It is the molecular function (GO:0005248) that enables sodium ions to cross the membrane through a channel whose opening depends on the membrane voltage.
What genes are involved in voltage-gated sodium channel activity?
The main genes are SCN1A-SCN11A, which encode the alpha subunits Nav1.1-Nav1.9, and SCN1B-SCN4B, which encode auxiliary beta subunits.
What is the role of SCN1A in the brain?
SCN1A encodes Nav1.1, a major sodium channel in inhibitory neurons; mutations cause Dravet syndrome and epilepsy.
How do voltage-gated sodium channels open?
Depolarization moves the S4 voltage sensors, triggering a conformational change that opens the pore.
What is fast inactivation of sodium channels?
It is a rapid closure of the pore mediated by the III-IV linker, which terminates the sodium current within milliseconds.
What diseases are linked to sodium channel mutations?
Epilepsy, cardiac arrhythmias, chronic pain, and some cancers are associated with Nav channel dysfunction.
How can I study voltage-gated sodium channel activity in the lab?
Patch-clamp electrophysiology, structural biology, fluorescence imaging, and CRISPR-based genetic models are commonly used.
What are the therapeutic targets among sodium channels?
Nav1.7, Nav1.8, and Nav1.5 are major targets for pain and cardiac drugs, respectively.
Can CRISPR be used to model sodium channel diseases?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to study channelopathies.
What is the difference between Nav1.7 and Nav1.8?
Nav1.7 is important for pain signaling and is tetrodotoxin-sensitive, while Nav1.8 is tetrodotoxin-resistant and contributes to inflammatory pain.
Conclusion
Voltage-gated sodium channel activity (GO:0005248) is a fundamental molecular function that drives electrical signaling in excitable cells and is implicated in a wide range of diseases. Understanding its mechanism, regulation, and pharmacology requires integrated approaches from electrophysiology, structural biology, and genetics. CRISPR-based cell models provide a powerful way to dissect the causal roles of specific SCN genes and to test therapeutic hypotheses. As research advances, targeting Nav channels with subtype-selective modulators holds promise for treating pain, epilepsy, arrhythmias, and cancer.
References
- 1. Catterall WA. 2023. Voltage gated sodium and calcium channels: Discovery, structure, function, and Pharmacology.. Channels (Austin) 17(1):2281714 PMID: 37983307
- 2. McMahon KL et al.. 2024. Voltage-Gated Sodium Channel Inhibition by µ-Conotoxins.. Toxins (Basel) 16(1) PMID: 38251271
- 3. Chen H et al.. 2024. Structural mechanism of voltage-gated sodium channel slow inactivation.. Nat Commun 15(1):3691 PMID: 38693179
- 4. McDougall JJ et al.. 2024. Analgesic potential of voltage gated sodium channel modulators for the management of pain.. Curr Opin Pharmacol 75:102433 PMID: 38277942
- 5. Lopez-Mateos D et al.. 2026. Exploring voltage-gated sodium channel conformations and protein-protein interactions using AlphaFold2.. J Gen Physiol 158(2) PMID: 41411077
- 6. Martin-Eauclaire MF et al.. 2019. Serotherapy against Voltage-Gated Sodium Channel-Targeting αToxins from Androctonus Scorpion Venom.. Toxins (Basel) 11(2) PMID: 30678116
- 7. Ai Y et al.. 2023. Role of the voltage‑gated sodium channel Nav1.6 in glioma and candidate drugs screening.. Int J Mol Med 51(6) PMID: 37052249
- 8. Mercier A et al.. 2018. Sodium Channel Trafficking.. Handb Exp Pharmacol 246:125-145 PMID: 28939974
